LIFW:NSD-MSP Recovery Inc. (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 0.5029

Change

-0.02 (-3.38)%

Market Cap

USD 0.09B

Volume

0.22M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-21 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

-0.04 (-0.05%)

USD 34.92B
HQY HealthEquity Inc

+0.02 (+0.02%)

USD 7.36B
RCM R1 RCM Inc

+0.04 (+0.32%)

USD 5.27B
GDRX Goodrx Holdings Inc

+0.20 (+2.62%)

USD 3.15B
PGNY Progyny Inc

+0.40 (+1.53%)

USD 2.46B
TXG 10X Genomics Inc

-0.29 (-1.46%)

USD 2.35B
CERT Certara Inc

-0.27 (-1.98%)

USD 2.24B
PRVA Privia Health Group Inc

-0.18 (-1.07%)

USD 2.04B
PINC Premier Inc

-0.12 (-0.65%)

USD 1.94B
BTSG BrightSpring Health Services I..

-0.15 (-1.39%)

USD 1.82B

ETFs Containing LIFW

FM iShares MSCI Frontier and.. 0.47 % 0.81 %

+0.05 (+0.18%)

USD 0.38B

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -77.85% 13% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.85% 13% F 3% F
Trailing 12 Months  
Capital Gain -95.24% 8% B- 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.24% 8% B- 2% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -30.46% 21% F 11% F
Dividend Return -30.46% 21% F 11% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.45% 43% F 39% F
Risk Adjusted Return -68.53% 27% F 14% F
Market Capitalization 0.09B 40% F 36% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector